Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DAREONᵀᴹ-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung Carcinoma

NCT06077500 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06077500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06077500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DAREONᵀᴹ-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung Carcinoma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 14, 2024
Completion date
April 1, 2027
Enrollment
46 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma (sclc)